An Isoxazoloquinone Derivative Inhibits Tumor Growth by Targeting STAT3 and Triggering Its Ubiquitin-Dependent Degradation

Background: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, with shorter five-year survival than other breast cancer subtypes, and lacks targeted and hormonal treatment strategies. The signal transducer and activator of transcription 3 (STAT3) signaling is up-regulated in various tumors, including TNBC, and plays a vital role in regulating the expression of multiple proliferation- and apoptosis-related genes. Results: By combining the unique structures of the natural compounds STA-21 and Aulosirazole with antitumor activities, we synthesized a class of novel isoxazoloquinone derivatives and showed that one of these compounds, ZSW, binds to the SH2 domain of STAT3, leading to decreased STAT3 expression and activation in TNBC cells. Furthermore, ZSW promotes STAT3 ubiquitination, inhibits the proliferation of TNBC cells in vitro, and attenuates tumor growth with manageable toxicities in vivo. ZSW also decreases the mammosphere formation of breast cancer stem cells (BCSCs) by inhibiting STAT3. Conclusions: We conclude that the novel isoxazoloquinone ZSW may be developed as a cancer therapeutic because it targets STAT3, thereby inhibiting the stemness of cancer cells.

[1]  Mubiao Liu,et al.  STAT3 inhibitor BBI608 reduces patient-specific primary cell viability of cervical and endometrial cancer at a clinical-relevant concentration , 2022, Clinical and Translational Oncology.

[2]  M. Tallman,et al.  Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. , 2021, The Lancet. Haematology.

[3]  Tingting Shi,et al.  CircRNA_ACAP2 Suppresses EMT in Head and Neck Squamous Cell Carcinoma by Targeting the miR-21-5p/STAT3 Signaling Axis , 2020, Frontiers in Oncology.

[4]  Om P. S. Patel,et al.  Antimalarial application of quinones: A recent update. , 2020, European journal of medicinal chemistry.

[5]  C. Colarossi,et al.  Radiosensitivity of Cancer Stem Cells Has Potential Predictive Value for Individual Responses to Radiotherapy in Locally Advanced Rectal Cancer , 2020, Cancers.

[6]  Y. Tu,et al.  MicroRNA‐148a‐3p suppresses epithelial‐to‐mesenchymal transition and stemness properties via Wnt1‐mediated Wnt/β‐catenin pathway in pancreatic cancer , 2020, Journal of cellular and molecular medicine.

[7]  Wei Huang,et al.  Targeting STAT3 in Cancer Immunotherapy , 2020, Molecular cancer.

[8]  A. Stein,et al.  Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Joshua A. Kritzer,et al.  Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors. , 2020, Bioorganic & medicinal chemistry.

[10]  Chen-Yang Shen,et al.  Tumorigenic and Metastatic Role of CD44−/low/CD24−/low Cells in Luminal Breast Cancer , 2020, Cancers.

[11]  L. Ye,et al.  MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug. , 2020, American journal of cancer research.

[12]  J. Slotta-Huspenina,et al.  STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy , 2020, International journal of molecular sciences.

[13]  Patrycja Czerwińska,et al.  Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6 , 2020, Oncoimmunology.

[14]  S. Salvi,et al.  Know your enemy: Genetics, aging, exposomic and inflammation in the war against triple negative breast cancer. , 2020, Seminars in cancer biology.

[15]  Kai Zhu,et al.  Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? , 2019, European journal of medicinal chemistry.

[16]  Liu Liu,et al.  A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. , 2019, Cancer cell.

[17]  Yue-Ting K Lau,et al.  Targeting STAT3 in Cancer with Nucleotide Therapeutics , 2019, Cancers.

[18]  Li Yan,et al.  STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review , 2019, Journal of experimental & clinical cancer research : CR.

[19]  W. Guo,et al.  Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product , 2019, Molecules.

[20]  L. Kong,et al.  A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy , 2018, Cell Death & Disease.

[21]  Yong Li,et al.  Cancer stem cell in breast cancer therapeutic resistance. , 2018, Cancer treatment reviews.

[22]  Zhishu Huang,et al.  Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors. , 2018, European journal of medicinal chemistry.

[23]  A. Taketomi,et al.  Interleukin‐6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy , 2017, Cancer science.

[24]  D. Brinza,et al.  Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy , 2017, npj Breast Cancer.

[25]  Ke Wang,et al.  Inhibitory effects of BMP9 on breast cancer cells by regulating their interaction with pre-adipocytes/adipocytes , 2017, Oncotarget.

[26]  C. Müller,et al.  Anthraquinones As Pharmacological Tools and Drugs , 2016, Medicinal research reviews.

[27]  Haluk Resat,et al.  Constitutive activation of STAT3 in breast cancer cells: A review , 2016, International journal of cancer.

[28]  Kuiwu Wang,et al.  Design, synthesis, molecular docking studies and anti-HBV activity of phenylpropanoid derivatives. , 2016, Chemico-biological interactions.

[29]  Chunxiao Liu,et al.  Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin , 2016, Cancer medicine.

[30]  J. Nemunaitis,et al.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer , 2015, Science Translational Medicine.

[31]  D. Ross,et al.  Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity. , 2015, Angewandte Chemie.

[32]  E. Laurini,et al.  Hitting the right spot: Mechanism of action of OPB‐31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) , 2015, Molecular oncology.

[33]  Yeong Shik Kim,et al.  Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. , 2015, Cancer letters.

[34]  Derek J. Wilson,et al.  Changes in Signal Transducer and Activator of Transcription 3 (STAT3) Dynamics Induced by Complexation with Pharmacological Inhibitors of Src Homology 2 (SH2) Domain Dimerization* , 2014, The Journal of Biological Chemistry.

[35]  S. Hilsenbeck,et al.  STAT3 Signaling Is Activated Preferentially in Tumor‐Initiating Cells in Claudin‐Low Models of Human Breast Cancer , 2014, Stem cells.

[36]  H. Zhang,et al.  Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients , 2014, Oncotarget.

[37]  Pornpimol Charoentong,et al.  High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer , 2014, BMC Cancer.

[38]  Kristin Reiche,et al.  Cell cycle, oncogenic and tumor suppressor pathways regulate numerous long and macro non-protein-coding RNAs , 2014, Genome Biology.

[39]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[40]  Y. Kwon,et al.  Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. , 2013, Cellular signalling.

[41]  J. Visvader,et al.  Cancer stem cells: current status and evolving complexities. , 2012, Cell stem cell.

[42]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  D. J. Jerry,et al.  Repression of Mammary Stem/Progenitor Cells by p53 Is Mediated by Notch and Separable from Apoptotic Activity , 2011, Stem cells.

[44]  P. Yue,et al.  A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. , 2010, Biochemical pharmacology.

[45]  S. Lipkowitz,et al.  Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. , 2010, Breast disease.

[46]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[47]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[48]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[49]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[50]  C. Jensen,et al.  Aulosirazole, a novel solid tumor selective cytotoxin from the blue-green alga Aulosira fertilissima , 1994 .

[51]  L. ‘. 't Hart.  Immunomodulation by quinones. A model for the use of quinones in the treatment of inflammation. , 1991, Pharmaceutisch weekblad. Scientific edition.